<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-allogene-swaps-cmo-new-chief-exec" hreflang="en">Chutes & Ladders—Allogene swaps in CMO as new chief exec</a>
Allogene Therapeutics has appointed Zachary Roberts as its new CEO, succeeding co-founder David Chang, while Immunic has hired Erik Lundgren as CEO to lead its commercialization efforts for a multiple sclerosis candidate. Additionally, Zai Lab's COO Josh Smiley has departed as part of a leadership restructuring aimed at improving operational efficiency.
The key insight for someone tracking healthtech and biotech is the strategic leadership change at Allogene Therapeutics, where Zachary Roberts, M.D., Ph.D., has been appointed CEO. Roberts' experience and previous success in pioneering a novel trial design targeting minimal residual disease in lymphoma could signal Allogene's potential for innovative advancements and impact in the CAR-T space, making it a company to watch for future breakthroughs.